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The low gene transfer efficiency of chitosan-DNA polyplexes is a consequence of their high stability and consequent slow DNA
release. The incorporation of an anionic polymer is believed to loosen chitosan interactions with DNA and thus promote higher
transfection efficiencies. In this work, several formulations of chitosan-DNA polyplexes incorporating hyaluronic acid were
prepared and characterized for their gene transfection efficiency on both HEK293 and retinal pigment epithelial cells.The different
polyplex formulations showedmorphology, size, and charge compatiblewith a role in gene delivery.The incorporation of hyaluronic
acid rendered the formulations less stable, as was the goal, but it did not affect the loading and protection of the DNA. Compared
with chitosan alone, the transfection efficiency had a 4-fold improvement, which was attributed to the presence of hyaluronic
acid. Overall, our hybrid chitosan-hyaluronic acid polyplexes showed a significant improvement of the efficiency of chitosan-based
nonviral vectors in vitro, suggesting that this strategy can further improve the transfection efficiency of nonviral vectors.
1. Introduction
Nonviral gene therapy is currently limited by the lack of
vectors with gene transfer efficiency similar to viral vectors.
Chitosan is one of the most studied cationic polymers for
nonviral gene therapy, both in vitro and in vivo [1–3].
Although chitosan-based polyplexes (complexes of chitosan-
nucleic acids) have desirable characteristics for gene therapy
such as efficient nucleic acid encapsulation and protection
against degradation, they show low gene transfer efficiency,
which is the major obstacle to its use as a gene therapy vector
[1, 4]. Several studies suggest a direct correlation between the
stability of polyplexes and transfection efficiency, proposing
that the high stability and strong interactions between chi-
tosan and DNA are the cause for the low transfection results
[2, 5, 6]. Polyplex stability is thus a crucial parameter when
designing a polymer based gene delivery vector; it should
be stable enough to withstand the cellular internalization
process, but not too stable that once inside the cell it will not
release its therapeutic load [7, 8].
Approaches for improving the efficiency of chitosan-
mediated gene transfer focus on chemical modification of
chitosan and the incorporation of anionic biopolymers. We
have previously modified chitosan to incorporate disulfide
bonds that could be cleaved intracellularly, but the increase
in transfection efficiency was moderate [9]. The incorpora-
tion of anionic polymers, which destabilize polyplexes and
hence facilitate DNA release [4, 7, 8, 10, 11], is another
strategy that has shown promising results. Competition-
binding assays showed that the addition of alginate effectively
reduces the interaction strength between CS and DNA,
which improved DNA release and consequently transfection
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[10]. Other studies have shown that coating polyplexes with
hyaluronic acid (HA) enhanced internalization and trans-
fection in association with other cationic polymers, such as
polyethyleneimine [12, 13]. It has also been previously shown
that the incorporation of HA into the polyplex formulation
increased green fluorescent protein (GFP) expression and the
authors suggest this increase to be related to (1) improved
internalization due to interactions with the cellular surface,
(2) HA function as a transcription activator, and (3) HA
accumulation in the perinuclear region and cell nuclei [14].
Furthermore, several studies hypothesized that HA could be
used to improve targeting through the specific HA/CD44
receptor interaction and could be of value to both gene and
drug delivery strategies [14, 15].
In this work, we designed CS polyplexes incorporating
HA (CSHA) with two different molecular weights (MW)
in several CS to HA ratios and evaluated their potential in
vitro for gene delivery. While other studies have used CSHA
polyplexes targeting the anterior part of the eye [12, 14, 16],
this is, to our knowledge, the first report in the posterior
part of the eye. We have tested these formulations in cells
of the retinal pigment epithelium, a cell layer of the retina
that supports the overall health of the retina [17] and whose
function, when compromised, is implicated in several retinal
pathologies such as age-relatedmacular degeneration, among
others.
2. Materials and Methods
2.1. Materials. Chitosan (CS) with a MW of 15 kDa and a
degree of deacetylation of 84% was purchased from Poly-
sciences Inc., USA. Hyaluronic acid, with 132 or 214 kDa,
from here on designated HA132 or HA214, respectively, was
purchased from Lifecore Biomedical Inc., USA. All other
reagents were of analytical grade and were used without
further purification.
2.1.1. Plasmid and Cell Lines. A plasmid expressing enhanced
green fluorescent protein (GFP) driven by the cytomega-
lovirus promoter (kindly provided by Dr. Jean Bennett,
University of Pennsylvania, USA) was amplified in Top 10
bacteria and purified using a PlasmidMaxi kit (Qiagen, USA)
according to the manufacturer’s instructions. Plasmid DNA
(pDNA) was dissolved in TE buffer, and the concentration
was determined at 260 nm using a NanoDrop 2000c spec-
trophotometer (Thermo Scientific, USA).
Two cell lines were used in the cytotoxicity and transfec-
tion studies: human embryonic kidney 293 (HEK293) cells, a
cell line generally used to assess transfection efficiency, and
human retinal pigment epithelial cells (ARPE-19), a cell line
derived from normal human eyes. All cell culture reagents
were purchased from Sigma-Aldrich (USA).
2.2. Methods
2.2.1. Preparation of CS and CSHA Polyplexes. CS polyplexes
were prepared as previously described by our lab [9]. Briefly,
a CS solution (0.02% (W/V) in 0.1M acetic acid, pH 3) and
a 5mM of sodium sulphate solution were separately heated
to 55∘C. Equal volumes of both solutions were quickly mixed
together, vortexed for 30 s, placed on ice, and stored at 4∘C.
CSHA polyplexes were prepared using a HA132 or HA214
solution (0.1% (W/V) inMilliQwater).The followingCS :HA
weight ratios: 3 : 1, 4 : 1, 5 : 1, 7 : 1, and 10 : 1, were used, keeping
constant the CS amount (50 𝜇g) and varying the HA amount.
In order to use equal volumes of both solutions, HA was
diluted in 5mM sodium sulphate and then mixed with the
CS solution, as described above.





− ratio of 5 : 1, 50𝜇g of CS and 16.1 𝜇g
of pDNA were used. pDNA was mixed with the sodium
sulfate solution and this solution was mixed with the CS
solution, as described above, thus producing CSpDNA 5 : 1 or
CSHApDNA 5 : 1 polyplexes. The 5 : 1 ratio was chosen based
on previous results for CS-pDNA, which showed this ratio to
be the most appropriate for cell transfection [1, 9].
2.2.2. Polyplex Characterization. Size analysis was performed
using dynamic light scattering (DLS) and noninvasive back-
scatter technology with a detection angle of 173∘, and zeta
potential (ZP) wasmeasured using laser Doppler velocimetry
and phase analysis light scattering technology (Zetasizer
Nano ZS, Malvern instruments, UK). All polyplexes were
analyzed in ddH
2
O at 25∘C. The polydispersity index (PdI)
was calculated based on DLS measurements using the Zeta-
sizer Nano Series software v 6.20.
Transmission electronmicroscopy (TEM, JEOL JEM-1011
electron microscope, Tokyo, Japan) was used to evaluate the
morphology of the polyplexes. Prior to analysis, samples were
stained with 2% (w/v) phosphotungstic acid and placed on
copper grids with Formvar films.
2.2.3. Evaluation of pDNA Encapsulation Efficiency and Pro-
tection from Degradation. The pDNA complexation, reten-
tion, and integrity in the polyplexes were assessed by gel
electrophoresis. Free pDNA and polyplexes were separately
incubated with 1 unit of DNAse I (Sigma-Aldrich, USA) for
15min at 37∘C. The reaction was stopped by 1𝜇L of a 50mM
EDTA solution and heated at 70∘C for 10min.The integrity of
the pDNA was then analyzed by agarose gel electrophoresis
in 1% (W/V) agarose in TAE buffer with ethidium bromide.
Gels were subjected to a 70mV voltage for 1.5 h and further
visualized under UV light (AlphaImager, Alpha Innotech,
USA).
2.2.4. Evaluation of Polyplex Stability. Polyplex stability was
evaluated in two different ways: stability at physiological
temperature (37∘C) and pH (7.4) and also long-term stability
(4∘C, pH 7.4). Briefly, polyplexes were incubated in equal
volumes of either PBS or DMEM (with 10% FBS [fetal bovine
serum]) at 37∘C for 1 to 3 days. Polyplex stability, evaluated by
pDNA retention, was performed as described in the previous
section. For evaluation of long-term stability, polyplexes were
incubated at 4 or 37∘C and their size and polydispersity
monitored weekly for up to 23 weeks.
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Table 1: Composition, size, polydispersity, and zeta potential of CS and CSHA polyplexes.
Particle pDNA§ HA (kDa) CS :HA ratio Size (⌀, nm) Polydispersity Zeta potential (mV)
CS − — — 402.8 ± 94.10 0.273 ± 0.128 19.9 ± 2.38
CSpDNA + — — 241.8 ± 64.04∗∗∗∗ 0.266 ± 0.068 20.09 ± 2.28
CSHA1 −
132
5 : 1 351.3 ± 24.79
## 0.245 ± 0.092 23.57 ± 1.19
CSHA2 + 328.1 ± 50.25 0.260 ± 0.088 24.18 ± 3.06
CSHA3 − 7 : 1 334.7 ± 62.76
# 0.157 ± 0.066 18.20 ± 2.30
CSHA4 + 267.7 ± 30.52∗∗∗∗ 0.293 ± 0.080 19.08 ± 3.56
CSHA5 −
214
5 : 1 360.5 ± 69.66
## 0.183 ± 0.064 24.29 ± 3.19
CSHA6 + 322.5 ± 69.94 0.270 ± 0.097 23.04 ± 2.31
CSHA7 − 7 : 1 345.6 ± 43.05
# 0.243 ± 0.068 20.84 ± 4.48
CSHA8 + 284.9 ± 34.31∗∗∗ 0.298 ± 0.065 20.00 ± 2.60
§Presence or absence of pDNA in the formulation is indicated by + or −, respectively. Values marked with asterisks are statistically different to CS value,
∗∗∗
𝑃 < 0.001, ∗∗∗∗𝑃 < 0.0001. Values marked with cardinals are statistically different to CSDNA value, #𝑃 < 0.05, ##𝑃 < 0.01 (statistical differences
determined by Tukey’s multiple comparisons test).
2.2.5. Cell Culture. Cells were cultured at 37∘C, under a
5% CO
2
atmosphere. Different culture media were used,
according to each cell’s specifications: HEK293 in Dulbecco’s
Modified Eagle’s Medium (DMEM) and ARPE-19 in DMEM
mixture with F-12 HAM, both supplemented with 10% of
fetal bovine serum, 1% penicillin/streptomycin, and 1% Glu-
tamine.
2.2.6. Cytotoxicity Evaluation. AnMTT assay was performed
to evaluate the cytotoxicity of the polyplexes. Cells were
plated at a density of 1.5 × 104 cells/well in 48-well flat
bottom tissue culture plates and the assay was carried out
as described previously [9]. Cells were incubated in culture
medium containing different amounts of polyplexes (from
0.667 up to 13.3 𝜇g of CS per cm2 of growth area) for 72 h. As
positive and negative controls of cell viability, cells cultured
in standard cell culture conditions and cells incubated with
a latex extract in culture medium (1.5 cm2/mL) were used,
respectively. Absorbance was measured using a microplate
reader (Tecan Infinite 2000, USA), at 570 and 630 nm, for
cell viability/formazan formation and background, respec-
tively. After subtracting the background (OD = OD570 nm –
OD630 nm), cell viabilitywas calculated as follows: cell viabil-
ity (%) = (ODsample)/(ODcontrol) × 100, where ODcontrol
and ODsample are cells not challenged and challenged
by polyplexes, respectively. Each value was averaged from
triplicates and each experiment was carried out thrice.
2.2.7. Transfection Studies. For the transfection studies, cells
were plated at 1 × 105 cells/well in 6-well tissue culture plates.
FuGENE HD (Promega, USA) was used as positive trans-
fection control according to the manufacturer’s instructions.
CS and CSHA polyplexes were added to plated cells at a
ratio of 1 𝜇g of pDNA per well and further incubated for
72 h. Nontransfected cells were used as negative transfection
control.
Transfection efficiency was evaluated quantitatively by
flow cytometry by scoring GFP positive cells (FACScalibur,
BD Biosciences, USA) using FL-1H, green channel. A total of
1 × 105 events were counted for each sample. The percentage
of positive events corresponds to the gated events minus the
nontransfected cells.
2.2.8. Statistical Analysis. Results presented are mean ±
standard deviation of at least three independent experiments.
Statistical analysis was performed with GraphPad Prism 5
software. Data were subjected to analysis of variance (one-
and two-way ANOVA) and multiple comparisons tests using
a confidence interval of 95%.
3. Results
3.1. Size, Polydispersity, Surface Charge, andMorphology. The
initial step in polyplex characterization was the determi-
nation of polyplexes size, polydispersity (PdI), and surface
charge (by zeta potential, ZP), and the results are presented
in Table 1. For some of the tested CS :HA ratios (3 : 1, 4 : 1, and
10 : 1) we observed aggregation and consequently large sizes
and high PdI. These ratios were not tested further (data not
shown).
Polyplexes formulated without pDNA had sizes between
334.7 ± 62.76 nm and 402.8 ± 94.10 nm while those formu-
lated with pDNA revealed sizes between 241.8 ± 64.04 nm
and 328.1 ± 50.25 nm. The observed decrease in size is sta-
tistically different between CS polyplexes and pDNA loaded
polyplexes CSDNA, CSHA4, and CSHA8; differences were
also found between CSDNA polyplexes and pDNA unloaded
CSHA formulations.
All mean PdI values are under 0.300, reflecting homo-
geneous preparations. The only statistically significant dif-
ferences found were between formulations CSHA3 and
CSHA4 and CSHA3 and CSHA8 (𝑃 ≤ 0.05). These might
reflect minor differences in the homogeneity of the polyplex
suspensions mainly due to the presence of an additional
anionic compound in the mixture. Polyplexes were produced
as a single homogeneous preparation as illustrated by the
DSL size distribution graphs (Figure 1), where no secondary
peaks were observed. Regarding the surface charge of the
polyplexes, all displayed a positive charge with ZP values
between 18.20± 2.30 and 24.29± 3.19.TheZP values that were
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Figure 1: Dynamic light scattering raw data representative graphs for CSHA polyplexes: (a) without pDNA and (b) with pDNA.
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Figure 2: TEM microphotographs of CSHA polyplexes showing that different formulations have a regular, close to spherical morphology
(amplification: 100,000x, scale bar represents 2 𝜇m).
found to be statistically different were only for CSHA2 versus
CSHA3 and CSHA3 versus CSHA5 (𝑃 ≤ 0.05).
The morphology of the polyplexes was also analyzed
by TEM and the microphotographs revealed near spherical
polyplexes with sizes consistent to the ones determined by
DSL (Figure 2).
3.2. pDNA Complexation and Protection from DNase Degra-
dation. The second step in the characterization of the poly-
plexes was to evaluate if the presence of HA in the different
formulations affected pDNA complexation and protection
against nuclease degradation. All formulations complexed
pDNA successfully, as observed by the absence of pDNA
migration in an agarose gel (Figures 3(a) and 3(b)). Polyplexes
without pDNA (CS and CSHA) were used as controls and, as
expected, did not produce any detectable signal.These results
were further confirmed by performing the same experiment
in a 0.3% agarose gel (Figure 4).
Regarding pDNA protection against nuclease degra-
dation, all formulations showed a similar behavior, with
no detectable pDNA degradation (Figures 3(c) and 3(d)).
Uncomplexed pDNA was used as a control and, as expected,
was completely degraded by DNase I.
3.3. Polyplex Stability. Stability at physiological conditions is
an important factor since polyplexes should be stable enough
to protect pDNA and only release it once it has reached the
intracellular milieu. We therefore tested the stability of the
polyplexes at physiological pH and in the presence of serum,
to mimic in vivo conditions, by incubating the polyplexes
with PBS (pH 7.4) or DMEM with 10% FBS, respectively.
No detectable pDNA release was observed regardless of the
formulation and period of incubation (Figure 5).
The shelf life of the produced polyplexes is also an
important factor to consider. Long-term stability of the
polyplexes was evaluated at 4 and 37∘C by analysis of their
size and PdI (Figure 6). Results depicted in Figure 6 were
evaluated by variance analysis (1-wayANOVA) andDunnett’s
post hoc test to compare values to the starting time point
(𝑡 = 0). All CSHA formulations performed very similarly and
therefore the results shown for formulations CSHA7 and 8 are
representative of the other CSHA formulations.
The results showed that both size and PdI directly
increased with temperature and that all tested formulations
remained stable at 4∘C for an extended period of time (up to
13 weeks). The size of CSDNA polyplexes remained constant
throughout time. The presence of pDNA in the formulation
seemed to increase stability in CS formulations. Although
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Figure 3: Polyplexes encapsulation efficiency and nuclease protection analyzed by 1% agarose gel electrophoresis, DNA visualized with
ethidium bromide, (a) and (b) pDNA encapsulation in CSpDNA and CSHApDNA polyplexes, respectively, and lanes positive for polyplexes
but negative for pDNA represent unloaded polyplexes. DNA is protected against DNase I digestion: (c) CSpDNA and (d) CSHApDNA
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Figure 4: Polyplexes encapsulation efficiency analyzed by 0.3%
agarose gel electrophoresis, DNA visualized with ethidium bromide,
and lanes positive for polyplexes but negative for pDNA represent
unloaded polyplexes.
there were no statistical differences in the size of CSDNA
polyplexes, their PdI at 37∘C started to increase, reflecting
their decreasing stability at this temperature, after 49 days
(Figure 6). Also, measurements of some formulations were
discontinued due to visible aggregation and/or insufficient
volume, hence the difference in the depicted time points.
As aimed, formulations containing HA and pDNA were
less stable probably due to increased repulsion between
charged groups. The stability of CSHA8 formulation
decreased after 119 days at 4∘C and much earlier at 37∘C (63
days), as can be observed by the increase in size and PdI
(Figure 6).
3.4. InVitro Studies. Cytotoxicity of the developed polyplexes
was evaluated using an MTT assay in the retinal cell line
(ARPE-19, Figure 7). For HEK293 cells, our previous studies
have indicated absence of cytotoxicity [9]. Statistical analysis
revealed no differences between CS and CSHA formulations.
Cell viability was above 75% regardless of formulation and
concentration, except for the highest concentration tested,
which caused a decrease in cellular viability, with values
below 50% for all formulations. However, this concentration
is above the range to be used in vivo.
One of the key points of our study was to evaluate if the
introduction ofHAwould affect the stability of the polyplexes
to facilitateDNA release and hence increase their transfection
efficiency. CS and CSHA formulations with pDNA coding for
GFP were tested both in the retinal cell line ARPE-19 and in
HEK293 cells. The latter were used as a transfection control,
as their permissibility in terms of transfection is widely
accepted. As a control of the GFP expression system we used
FuGene HD, a commercial reagent. The percentage of GFP
positive cells 72 h after transfection is presented in Figure 8.
Results showed that the transfection efficiency varied with
cell line and type of formulation. HEK293 cells displayed
higher levels of GFP expressionwhen comparedwith the RPE
cell line, as expected, based on their different mitotic rates.
All formulations incorporating HA present increased GFP
expression when compared to CS polyplexes, with CSHA
polyplexes showing a near 4-fold increase in transfection
efficiency in HEK293 cells.
4. Discussion
4.1. Polyplexes. This work aims to evaluate the effect that
incorporating HA into CS polyplexes would have in the
stability of the polyplexes and in their transfection efficiency.
In summary, the characterization of the polyplexes revealed
differences in size for pDNA loaded and unloaded polyplexes,
but not betweenCS andCSHApolyplexes.This size difference
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Figure 5: Polyplexes remain stable at physiological conditions, (a) CSpDNA and (b) CSHApDNA polyplexes after incubation in PBS or
DMEM with 10% FBS at 37∘C. Polyplex pDNA retention analyzed by 1% agarose gel electrophoresis and pDNA visualized with ethidium
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Figure 6: Particle stability at 4∘C (left column) and 37∘C (right column) as verified by continued monitoring of their size (upper row) and
polydispersity (lower row). Significant differences to initial value were determined by Dunnett’s multiple comparisons test (∗∗∗∗𝑃 < 0.0001,
∗∗∗
𝑃 < 0.001, ∗∗𝑃 < 0.01, ∗𝑃 < 0.05).
























Figure 7: Cytotoxicity in RPE cell line (ARPE-19), given as percent-
age of viable cells after 72 h incubation with polyplexes at increasing
concentrations. Polyplex concentration is given in total CS 𝜇g in
polyplexes per cm2 of growth area.
between polyplexes with and without pDNA has been previ-
ously observed and is in accordance with the literature, since
CS establishes strong interactions with negatively charged
pDNA that contribute to a higher chain entanglement, thus
producing smaller polyplexes [9].
Variations in size and surface charge were expected after
the incorporation of HA into the formulation, since it has
been shown previously that an increase in size and decrease
in surface charge associated with HA content [12, 14]. In our
study no effect of HA was observed in either size or surface
charge. When addressing the effect of the MW of HA on
the size of polyplexes, studies have shown the formation of
smaller polyplexes with HA of increasing MW and also with
the use of higher CS :HA ratios [11]. In this aspect, our results
are well correlated with the literature, since using HA with a
highMWproduced polyplexes with smaller size and positive
surface charge, whereas the use of low ratios increased sizes
and decreased surface charge, causing aggregation (data not
shown) as shown by Duceppe and Tabrizian (2009) [11].
It has also been suggested that the MW of the anionic
polymer can influence the morphology of the polyplexes [11].
This was not observed in our study, since no morphological
differences were noticeable either amongCSHA formulations
or between CS and CSHA polyplexes. We attribute this
dissimilarity of our results with the literature to differences
in the characteristics of the polymers and polyplexes such
as MW and CS :HA ratios used in our study. Also, this
difference in polyplex behaviormight be related to differences
in the localization and degree of incorporation of HA in the
polyplexes [14]. During the chain entanglement process HA
chains may have been trapped in the interior of the polyplex,
thus not contributing to a significant decrease in surface
charge.
4.2. Stability. Previous studies have shown that HA can
influence the stability of polyplexes without affecting pDNA
binding to CS [8]. Our results support these findings and
also show that polyplexes remain stable at physiological
conditions and are able to protect pDNA from nuclease
degradation. Only in the long-term stability assay a decrease
in polyplex stability was observed in CSHA polyplexes, more
pronounced at 37∘C.
4.3. Cytotoxicity. Polyplex charge is also an important param-
eter due to its relation to toxicity and transfection efficiency,
as some authors have shown that a reduction in the positive
charge results in an increase in transfection efficiency asso-
ciated with a decrease in toxicity [18, 19]. A decrease in CS
polyplex cytotoxicity with increasing amounts of HA in their
formulations has been reported byDeLa Fuente et al. (2008),
but our results show no such differences when either different
CS :HA ratios or MW were used [14]. Since no decrease in
surface charge was observed, we expected the incorporation
of HA into the polyplexes to have no significant effect in the
cytotoxicity. Nevertheless, considering the concentrations to
be used in vivo our polyplexes can be considered a safe option
for gene delivery.
4.4. Transfection. It is believed that one of the major causes
of low transfection with polyplexes is their high stability and
consequently inefficient and slow DNA delivery [8, 11]. Con-
sidering that all formulations displayed similar size, surface
charge, and cytotoxicity, this suggests that the introduction
of HA affected the interactions between CS and pDNA and
modulated the release behavior, thereby resulting in a more
efficient transfection. The observed transfection efficiency
improvement over CS formulations may also be related to
increased cellular internalization since it has been shown
previously by de la Fuente that HA containing polyplexes can
be internalized via interactions with the membrane CD44
receptor [14]. Recent studies with the same cell lines but using
a lipid-based delivery system also containingHA corroborate
our results and also support the idea that HA enhances the
transfection efficiency by modulating the DNA condensation
degree in the vector. The same study also states that the
participation of the CD44 receptor in the internalization of
the vectors is an important factor for increased transfection
[20].
Similar to the results observed for HEK293 cells, a trend
of higher GFP expression levels was observed when ARPE-
19 were transfected with CSHA polyplexes, but it is not
statistically significant. One possible explanation for this is
their dividing rate, which is considerably lower than the one
of HEK293 cells. The fact that cell lines with different mitotic
rates were transfected demonstrates the versatility of our
vectors and paves the way to possible future applications in
other tissues. Additionally, it is known that the expression of
CD44, the receptor for HA, in RPE is affected both by their
proliferative state and by confluence, which might explain
these results [21]. It has also been described that CD44 is
increased in pathological conditions such as RPE wound
repair and choroidal neovascularization [22, 23]. This would
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Figure 8: Transfection efficiency 72 h after transfection as percentage of GFP positive cells. Statistical differences were calculated using Tukey
and Dunnett’s multiple comparisons test (∗∗∗∗𝑃 < 0.0001, ∗∗𝑃 < 0.01, ns—not significant).
suggest that polyplex CD44-dependent internalization in
vivo and in a pathological situation could be greatly increased
when comparedwith in vitro results. Based on this, our results
lay the foundation for the use of CSHA polyplexes for gene
delivery in animal models of retinal diseases.
5. Conclusions
In our study we describe the characterization of a hybrid
polyplex for retinal nonviral gene therapy. The polyplexes
containing both cationic (CS) and anionic (HA) polymers
display an improved performance over the previously devel-
oped chitosan-based polyplexes. The incorporation of HA
into the polyplexes resulted in a decrease in polyplex stability
that most likely enabled a more rapid pDNA release whilst
still protecting pDNA from degradation.
CSHA formulations showed an increase in in vitro cell
transfection, which suggests that this strategy might be very
effective in vivo, especially in retinal cells expressing CD44
and in pathological situations where CD44 is known to
be involved, allowing cellular targeting by HA-containing
formulations through CD44 interaction.
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